Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | MARK3 | P27448 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.49 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706679 | 0.85 | ADK (0.42) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL19718903 | 0.85 | DYRK3 (0.49) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL25241181 | 0.85 | ADK (0.41) | DYRK1AADKSRCLCKTEK | |
| SCHEMBL25282686 | 0.85 | ADK (0.42) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL8441851 | 0.84 | DYRK3 (0.54) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL20162777 | 0.84 | FLT3 (0.40) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL26554801 | 0.84 | DGAT1 (0.33) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL15672742 | 0.84 | DYRK3 (0.48) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL15400905 | 0.82 | CYP1A2 (0.35) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL29720975 | 0.81 | LCK (0.51) | FLT3SRCLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| US-8889666-B2 | Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8889666-B2 | Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2657233-B1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| EP-2722332-A1 | QUINOLYLPYRROLOPYRIMIDYL FUSED-RING COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-20140057899-A1 | QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057899-A1 | QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| EP-2657233-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | DYRK3 1999/4885ROCK2 3915/4885PRKD3 3235/4885 |
| US-20140057899-A1 | QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF | EGFR, JAK2, ABL1 | DYRK3 1271/4885ROCK2 1176/4885PRKD3 2208/4885 |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | NFXL1, ZFX, CXXC5 | DYRK3 1260/4885ROCK2 1347/4885PRKD3 3471/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | DYRK3 1991/4885ROCK2 2468/4885PRKD3 736/4885 |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | DYRK3 288/4885ROCK2 109/4885PRKD3 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.